Company Tagline
Developing a new class of ADCs based on NMT inhibition to treat cancer
Industry Category
Business Keywords
Company Description
Myricx Bio is at the forefront of biotechnology research, dedicated to developing a novel class of Antibody Drug Conjugates (ADCs) for cancer treatment. Focusing on NMT inhibition, Myricx Bio is committed to innovation and the advancement of therapeutic solutions in oncology.
Located in London, at Kings Cross, Myricx Bio leverages cutting-edge research and development to create selective cytotoxic payloads. The company's approach aims to provide more effective and targeted cancer therapies, contributing significantly to the field of biotechnology.
Myricx Bio is dedicated to pushing the boundaries of scientific discovery and improving patient outcomes. We invite the management team at Myricx Bio to enhance this profile further by creating a customized company showcase and product listing on our platform, highlighting the unique aspects of their work.
Key Personnel / Employees
Similar Companies
Other organizations in the same industry
Sealac Ltd
Biotechnology-ResearchOrganic and sustainable harvest, of marine seaweed for Human, Animal and Plant nutrition.
Guwahati HeredityBio group
Biotechnology-ResearchHands-on Training and Research at Heredity Biosciences, Guwahati: Empowering Careers in Biosciences
Block Biosciences
Biotechnology-ResearchIntercepting the spread of cancers to the brain.
Deep Piction
Biotechnology-ResearchAI-driven & sustainable biotech R&D Towards animal-free innovations
Alternative Company Names
This company is also known as